Pfizer Limited (PFIZER) Fair Value & Analysis
Healthcare · IN · Market cap ₹209B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹4,405 – ₹5,767 · fair‑value band ₹2,606 – ₹4,123 · the ₹4,569 price screens above the ₹3,431 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pfizer Limited (PFIZER) currently trades at ₹4,569, while our model-based Fair Value estimate is ₹3,431 — implying the stock looks roughly 24.9% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Pfizer Limited generated revenue of ₹25.2B at a net margin of 28.7%. Revenue grew 6.3% year over year. It earns a return on equity of 17.2%. The balance sheet holds a net cash position of ₹30.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Pfizer Limited reported revenue of ₹25.2B in FY2026 versus ₹26.1B in FY2022, a compound −0.9%/yr. Reported net income was ₹7.2B in FY2026, compounding +4.2%/yr from FY2022.
Is PFIZER fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| AstraZeneca PLC A1ZN34 | R$150.60 | R$23.54 | -84% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pfizer Limited (PFIZER) undervalued?
What is the fair value of PFIZER?
What is the quality score of PFIZER?
What is the revenue of Pfizer Limited (PFIZER)?
What is the net profit margin of PFIZER?
Does Pfizer Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.